AI Science Tracker

National Center for Advancing Translational Sciences, National Institutes of Health

1 discovery from 2023

Discoveries

Machine-learning screening yields novel potent acetylcholinesterase and butyrylcholinesterase inhibitors

NCATS researchers trained machine-learning QSAR models and applied them to a roughly 360,000-compound library. Experimental colorimetric and orthogonal fluorescence assays confirmed new AChE/BChE inhibitors; the study reports 22 AChE and 67 BChE inhibitors with IC50 below 5 μM, including novel structural series, with some submicromolar compounds.

Technology: Ensemble comparison of machine-learning QSAR classifiers (including XGBoost, random forest, SVM, neural network and naïve Bayes)

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Experimental colorimetric and orthogonal fluorescence assays confirmed new AChE/BChE inhibitors; the study reports 22 AChE and 67 BChE inhibitors with IC50 below 5 μM, including novel structural series, with some submicromolar compounds.
  • Still unknown: These are biochemical inhibitor assays and early medicinal-chemistry leads; they do not establish brain exposure, in-vivo efficacy, safety or clinical benefit. Several known compounds were newly identified as inhibitors, so the count of all assay hits should not be described as entirely novel molecules.
  • AI role: Models trained on quantitative high-throughput screening data prioritized compounds in a ~360,000-compound collection for AChE/BChE inhibition and selectivity assays. Researchers tested 2,762 high-scoring compounds in colorimetric assays and used an orthogonal fluorescence assay to confirm predicted inhibitors; subsequent structure–activity analysis identified novel scaffolds.

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10688023/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 26 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.